185亿美元，创新药BD新纪录诞生！低位埋伏港股通创新药反攻机会

Core Insights - The strategic collaboration and licensing agreement between CSPC Pharmaceutical Group and AstraZeneca for the development of innovative long-acting peptide drugs has a potential transaction value of up to $18.5 billion, setting a new record for BD transactions among Chinese pharmaceutical companies [2][13]. Group 1: Transaction Details - The agreement includes an upfront payment of $1.2 billion and up to $17.3 billion in milestone payments [2][13]. - This transaction is part of a broader trend where multiple innovative drug BD transactions have been completed since the beginning of 2026, indicating a positive trend for Chinese innovative drugs going global [13][20]. Group 2: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown strong performance, leading its peers since 2025, with a return of 75.03% [4][17]. - The index is characterized by high purity, elasticity, and sharpness, demonstrating strong aggressiveness in the rebound of the innovative drug market [4][17]. Group 3: Historical Context - In 2025, the total value of innovative drug BD outbound licensing transactions from China reached $135.655 billion, with a total of 157 transactions, both setting historical highs [20][21]. - The historical annual returns for the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index from 2021 to 2025 were -22.72%, -16.48%, -19.76%, -14.16%, and 66.32% respectively [6][18].